Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ADH1B | P00325 | 2/20 | 0.40 |
| ▸ | ADH1C | P00326 | 2/20 | 0.40 |
| ▸ | ADH1A | P07327 | 2/20 | 0.40 |
| ▸ | ADH7 | P40394 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8417470 | 0.92 | TSHR (0.60) | TSHRALDH1A1POLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL8418522 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL25887058 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL17526606 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL8521009 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL8418749 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL8416880 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL8420290 | 0.90 | TSHR (0.57) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL9419694 | 0.85 | CYP2C19 (0.40) | TSHRALDH1A1CYP2C19MEN1GLA | |
| SCHEMBL22308323 | 0.84 | CYP2C19 (0.43) | TSHRALDH1A1POLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230235365-A1 | ENGINEERED RETRONS AND METHODS OF USE | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3086792-B1 | METHODS AND REAGENTS FOR RADIOLABELING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-10-12 | — | — | EP | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190255055-A1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-08-22 | — | — | US | disclosed |
| US-20190022247-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2019-01-24 | — | — | US | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| EP-1940841-B9 | COMPOUNDS COMPRISING A BIOLOGICAL TARGET RECOGNIZING PART, COUPLED TO A SIGNAL PART CAPABLE OF COMPLEXING GALLIUM | GUERBET SA (FR) | 2017-04-19 | — | — | EP | disclosed |
| EP-2646043-B1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20110217636-A1 | COLORED CURABLE COMPOSITION, COLOR FILTER AND METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2011-09-08 | — | — | US | disclosed |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-04-29 | — | — | US | disclosed |
| US-7666880-B2 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2010-02-23 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2008-04-10 | — | — | US | disclosed |
| EP-1599167-B1 | BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES HAVING AFFINITY FOR THE MELANOCORTIN RECEPTORS AND USE THEREOF AS A MEDICAMENT | SOD CONSEILS RECH APPLIC (FR) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | TSHR 4063/4885ALDH1A1 3602/4885POLB 1590/4885 |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | TSHR 64/4885ALDH1A1 2294/4885POLB 2937/4885 |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | HDAC1, HDAC5, HDAC11 | TSHR 3223/4885ALDH1A1 514/4885POLB 400/4885 |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | TSHR 2186/4885ALDH1A1 237/4885POLB 810/4885 |
| US-20190255055-A1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | ALDH2, ALDH1A1, ALDH3A1 | TSHR 3677/4885ALDH1A1 2/4885POLB 2089/4885 |
| US-20190022247-A1 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | LPAR1, LPAR2, LMNA | TSHR 1632/4885ALDH1A1 2355/4885POLB 267/4885 |
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | TSHR 2181/4885ALDH1A1 514/4885POLB 4575/4885 |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | TSHR 3563/4885ALDH1A1 1707/4885POLB 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.